Centaurus Financial, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Centaurus Financial, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	BUY	$182.66 - $235.53 $2,009 - $2,590	11 Added 1.48%	752 $151,000
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $3,339 - $4,343	18 Added 2.49%	741 $176,000
Q3 2022 Dec 05, 2022	BUY	$138.54 - $232.0 $3,186 - $5,336	23 Added 3.29%	723 $145,000
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $90,041 - $123,822	700 New	700 $119,000
Q4 2020 Jan 25, 2021	SELL	$122.97 - $147.0 $88,538 - $105,840	-720 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$104.21 - $156.44 $75,031 - $112,636	720 New	720 $107,000
Q3 2018 Nov 05, 2018	SELL	$87.52 - $122.67 $60,213 - $84,396	-688 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$88.31 - $107.8 $60,757 - $74,166	688 New	688 $68,000

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.